Anlitiks Inc.

We're excited to share a new research article titled "Healthcare Resource Utilization among Nursing Home Residents with Parkinson's Disease Psychosis: An Analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics," authored by Dilesh Doshi, Nazia Rashid, Daksha Gopal, and Krithika Rajagopalan. This article was published in the Journal of Comparative Effectiveness Research and examines how different medications affect the healthcare services used by nursing home residents with Parkinson’s Disease Psychosis. The findings highlight important differences in healthcare usage, showing how specific treatments can benefit these vulnerable patients. You can read the full article here: https://lnkd.in/dD-et8bT Thanks to Acadia Pharmaceuticals Inc. and Becaris Publishing Limited for supporting this significant work. #ParkinsonsDisease #PsychosisResearch #HealthcareUtilization #ComparativeEffectiveness #MedicalResearch #FDAApproved #PatientCare #PublicHealth

We’re excited to share a new research article titled "Healthcare Resource Utilization and Costs among Treatment-Naïve People with HIV in State Medicaids: Analysis of Multi-Tablet vs. Single-Tablet Antiretroviral Regimen Initiators with and without Concurrent Mental Health Disorders," authored by M. Chen, M.J. Christoph, S. Park, F. Turkistani, A.R. Weinberg, and C. Trom. This article was published in the Journal of Comparative Effectiveness Research and explores how mental health disorders impact healthcare resource utilization and costs among treatment-naïve people with HIV initiating single- vs. multi-tablet antiretroviral regimens. The findings emphasize the importance of tailored treatment approaches to improve healthcare outcomes and reduce costs for vulnerable populations. You can read the full article here: https://bit.ly/3W2VkMA Thanks to our amazing collaborators and supporters for making this research possible! #HIVResearch #HealthcareCosts #MentalHealth #AntiretroviralTherapy #MedicaidInsights #MedicalResearch

🌟 Leadership Spotlight 🌟 Anlitiks Inc. is excited to announce Kitty Rajagopalan as our new Chief Executive Officer, effective September 2024. As President & Chief Scientific Officer of Anlitiks, Kitty has been instrumental in shaping global market access and health economics strategies for emerging biopharmaceutical companies. Kitty is a life sciences industry veteran and well-published executive with nearly 30 years of experience in the field of HEOR, RWE, Pricing, and Market Access. In her new role, she will continue to drive Anlitiks’ mission of delivering innovative solutions to the industry. Let’s congratulate Kitty Rajagopalan as she steps into this pivotal role! #Leadership #CEO #Anlitiks #MarketAccess #Innovation

Executive Leadership Announcement 📢 We are excited to welcome Sachin Palod as President at Anlitiks Inc. With over 20 years of experience managing P&Ls, scaling businesses, and driving large-scale transformations across healthcare, MedTech, and life sciences, Sachin has a proven track record of delivering impactful outcomes. His leadership and expertise will further strengthen our position in the market and enhance our ability to deliver impactful solutions. Please join us in welcoming Sachin Palod to the Anlitiks team! #Leadership #President #Anlitiks #MarketAccess #Innovation

We are excited to announce a webinar on the global evolution of real-world data (RWD) and real-world evidence (RWE) in regulatory approvals and health technology assessments! Join us to explore cutting-edge practices and real-world case studies from industry experts, enhancing your regulatory strategies and market access. 📅 Date: August 29th, 2024 🕒 Time: 11 am EDT / 4 pm BST / 5 pm CEST Don’t miss this opportunity to stay ahead in the rapidly evolving landscape! Register Today: https://bit.ly/3LX4yof #RealWorldData #RealWorldEvidence #RegulatoryApproval #HealthTechnology #Webinar

Discover the potential of real-world comparator cohorts in clinical trials! Join our upcoming webinar to explore advanced methodologies and impactful case studies. Learn how to integrate real-world data effectively to enhance your research and development outcomes. 📅 Date: August 22nd, 2024 🕒 Time: 11 am EDT / 4 pm BST / 5 pm CEST Gain insights from industry leaders and transform your clinical trial strategies! Register Now: https://bit.ly/3YwsPZT #ClinicalTrials #RealWorldData #ComparatorCohorts #ResearchInnovation #Webinar 

🌟 From Data to Decisions! 🌟 Anlitiks Inc. specializes in transforming real-world data into actionable insights. Our RapidAnalyzer(TM) Platform and strategic RWE-based solutions support life sciences companies in achieving market access and commercial goals. For more information, contact Tony Coughlan at tcoughlan@anlitiks.com or scan the QR code. #LifeSciences #RealWorldData #MarketAccess #HealthcareInnovation #AdvancedAnalytics #RWE

Join us for an insightful webinar on navigating the Joint Clinical Assessment (JCA) landscape in the EU! Learn about the strategic roadmap for pharmaceutical companies to leverage JCA for streamlined evaluations and faster market access. Discover the financial, regulatory, and operational implications from industry experts. 📅 Date: August 15th, 2024  🕒 Time: 11 am EDT / 4 pm BST / 5 pm CEST Register today: https://buff.ly/3LLNotT #ClinicalAssessment #JCA #MarketAccess #Webinar

We are excited to announce an upcoming webinar on leveraging real-world data and advanced analytics for drug development and commercialization! Learn from industry experts about advanced analytics techniques driving innovation and improving clinical outcomes. Join us on August 8th, 2024, at 12 pm EDT / 5 pm BST / 6 pm CEST to discover how real-world evidence can optimize product development and market access. Register Now: https://buff.ly/3xHkzLH #RealWorldData #DrugDevelopment #ClinicalOutcomes #Webinar 

📢 Happy to share our latest research article titled "Falls and Fractures among Nursing Home Residents Treated with Pimavanserin versus Other Atypical Antipsychotics: Analysis of Medicare Beneficiaries with Parkinson’s Disease Psychosis," authored by Dilesh Doshi, Nazia Rashid , Daksha Gopal and Krithika Rajagopalan . This study, recently published, delves into the comparative risk of falls and fractures among nursing home residents treated with different antipsychotic medications. The research underscores significant findings, indicating that residents treated with pimavanserin have a 37% lower risk of falls and fractures compared to those on other atypical antipsychotics, and a 41% lower risk compared to those on quetiapine. Read the full article here: https://lnkd.in/d3AbqnGr Thank you Acadia Pharmaceuticals Inc. and Becaris Publishing Limited for supporting this work. #HealthcareResearch #ParkinsonsDisease #Medicare #Pimavanserin #Quetiapine #MedicalResearch #Anlitiks #EvidenceBasedPractice